JP2021527656A5 - - Google Patents
Info
- Publication number
- JP2021527656A5 JP2021527656A5 JP2020570444A JP2020570444A JP2021527656A5 JP 2021527656 A5 JP2021527656 A5 JP 2021527656A5 JP 2020570444 A JP2020570444 A JP 2020570444A JP 2020570444 A JP2020570444 A JP 2020570444A JP 2021527656 A5 JP2021527656 A5 JP 2021527656A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- identity
- progranulin
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862686579P | 2018-06-18 | 2018-06-18 | |
| US62/686,579 | 2018-06-18 | ||
| US201862746338P | 2018-10-16 | 2018-10-16 | |
| US62/746,338 | 2018-10-16 | ||
| PCT/US2019/037695 WO2019246071A1 (en) | 2018-06-18 | 2019-06-18 | Fusion proteins comprising progranulin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527656A JP2021527656A (ja) | 2021-10-14 |
| JP2021527656A5 true JP2021527656A5 (https=) | 2022-06-27 |
| JP7517997B2 JP7517997B2 (ja) | 2024-07-17 |
Family
ID=67138158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570444A Active JP7517997B2 (ja) | 2018-06-18 | 2019-06-18 | プログラニュリンを含む融合タンパク質 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20210284702A1 (https=) |
| EP (1) | EP3807322A1 (https=) |
| JP (1) | JP7517997B2 (https=) |
| KR (1) | KR20210027377A (https=) |
| CN (1) | CN112424233A (https=) |
| AU (1) | AU2019288212B2 (https=) |
| BR (1) | BR112020025306A2 (https=) |
| CA (1) | CA3101202A1 (https=) |
| CL (1) | CL2020003255A1 (https=) |
| EC (1) | ECSP20081591A (https=) |
| IL (1) | IL279510B2 (https=) |
| MX (1) | MX2020012518A (https=) |
| PE (1) | PE20210323A1 (https=) |
| PH (1) | PH12020552189A1 (https=) |
| SG (1) | SG11202011743SA (https=) |
| TW (1) | TWI874321B (https=) |
| WO (1) | WO2019246071A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3280441T1 (sl) | 2015-04-07 | 2022-01-31 | Alector Llc | Protitelesa anti-sortilin in metoda njihove uporabe |
| AU2016270587B2 (en) * | 2015-05-29 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a disruption in a C9ORF72 locus |
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| LT3618928T (lt) | 2018-07-13 | 2023-04-11 | Alector Llc | Anti-sortilino antikūnai ir jų panaudojimo būdai |
| WO2020037150A2 (en) * | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
| JP7624919B2 (ja) * | 2018-10-16 | 2025-01-31 | デナリ セラピューティクス インコーポレイテッド | プログラニュリン関連障害を処置及びモニタリングするための方法 |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| PH12022551598A1 (en) * | 2019-12-23 | 2023-11-20 | Denali Therapeutics Inc | Progranulin variants |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| WO2021241616A1 (ja) | 2020-05-27 | 2021-12-02 | アステラス製薬株式会社 | 抗ヒトｎｒ１抗体誘導体 |
| US20210393787A1 (en) * | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
| JP7817757B2 (ja) * | 2020-09-18 | 2026-02-19 | アイユーシーエフ－エイチワイユー（インダストリー－ユニバーシティ コーオペレーション ファウンデーション ハンヤン ユニバーシティ） | ＰＴＰｓｉｇｍａ－Ｆｃ融合タンパク質およびそれを含む薬学組成物 |
| KR102666958B1 (ko) * | 2020-09-18 | 2024-05-23 | 한양대학교 산학협력단 | PTPsigma-Fc 융합단백질 및 이를 포함하는 약학 조성물 |
| WO2022082178A2 (en) | 2020-10-14 | 2022-04-21 | Denali Therapeutics Inc. | Methods for treating and monitoring frontotemporal dementia |
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| AU2022415476A1 (en) * | 2021-12-17 | 2024-07-04 | Denali Therapeutics Inc. | Fusion proteins comprising alpha-l-iduronidase enzymes and methods |
| EP4508206A1 (en) * | 2022-04-12 | 2025-02-19 | F. Hoffmann-La Roche AG | Fusion proteins targeted to the central nervous system |
| EP4526344A1 (en) * | 2022-05-16 | 2025-03-26 | Denali Therapeutics Inc. | Transferrin receptor-binding domains and proteins comprising the same |
| JP2026501108A (ja) * | 2022-12-06 | 2026-01-14 | プロテインキュア インコーポレイテッド | ソルチリンの標的化 |
| US20250000992A1 (en) | 2023-06-21 | 2025-01-02 | Eli Lilly And Company | Compounds for the delivery of granulin across the blood brain barrier |
| WO2025051953A1 (en) * | 2023-09-07 | 2025-03-13 | Novo Nordisk A/S | Sortilin-1 binders, constructs and uses thereof |
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
| WO2025166077A1 (en) * | 2024-01-31 | 2025-08-07 | Alector Llc | Compositions comprising progranulin and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120039865A1 (en) * | 2008-08-19 | 2012-02-16 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| SI3280441T1 (sl) * | 2015-04-07 | 2022-01-31 | Alector Llc | Protitelesa anti-sortilin in metoda njihove uporabe |
| HUE057952T2 (hu) * | 2015-06-24 | 2022-06-28 | Hoffmann La Roche | Anti-transzferrin receptor antitestek testreszabott affinitással |
| WO2018024162A1 (en) * | 2016-08-03 | 2018-02-08 | Sunshine Lake Pharma Co., Ltd. | Glp-1 fusion protein comprising mutated immunoglobulin fc portion |
| US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
| WO2018152285A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
-
2019
- 2019-06-18 WO PCT/US2019/037695 patent/WO2019246071A1/en not_active Ceased
- 2019-06-18 JP JP2020570444A patent/JP7517997B2/ja active Active
- 2019-06-18 CN CN201980039158.0A patent/CN112424233A/zh active Pending
- 2019-06-18 PE PE2020002083A patent/PE20210323A1/es unknown
- 2019-06-18 KR KR1020217001552A patent/KR20210027377A/ko not_active Ceased
- 2019-06-18 MX MX2020012518A patent/MX2020012518A/es unknown
- 2019-06-18 IL IL279510A patent/IL279510B2/en unknown
- 2019-06-18 BR BR112020025306-5A patent/BR112020025306A2/pt unknown
- 2019-06-18 EP EP19735097.8A patent/EP3807322A1/en active Pending
- 2019-06-18 SG SG11202011743SA patent/SG11202011743SA/en unknown
- 2019-06-18 TW TW108121124A patent/TWI874321B/zh active
- 2019-06-18 AU AU2019288212A patent/AU2019288212B2/en active Active
- 2019-06-18 CA CA3101202A patent/CA3101202A1/en active Pending
- 2019-06-18 US US17/253,391 patent/US20210284702A1/en not_active Abandoned
-
2020
- 2020-12-11 PH PH12020552189A patent/PH12020552189A1/en unknown
- 2020-12-16 EC ECSENADI202081591A patent/ECSP20081591A/es unknown
- 2020-12-16 CL CL2020003255A patent/CL2020003255A1/es unknown
-
2023
- 2023-04-12 US US18/299,458 patent/US20230406898A1/en not_active Abandoned
-
2025
- 2025-02-04 US US19/044,856 patent/US20260001925A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527656A5 (https=) | ||
| JP2021510162A5 (https=) | ||
| JP7397063B2 (ja) | 操作された二重特異性タンパク質 | |
| JP2023512450A5 (https=) | ||
| KR102514330B1 (ko) | Pd-1 및 lag-3와의 면역반응성을 가진 공유 결합된 디아바디, 및 그것의 사용 방법 | |
| ES2749457T3 (es) | Anticuerpos humanizados que reconocen la alfa-sinucleína | |
| JP6744856B2 (ja) | α−シヌクレインを認識する抗体を含む血液脳関門シャトル | |
| JP2025026880A (ja) | 操作されたＦｃコンストラクトに関する組成物及び方法 | |
| JP2021533779A5 (https=) | ||
| KR20190134997A (ko) | 항-tau 항체 및 이의 사용 방법 | |
| EP2985294A1 (en) | Recombinant antibody molecule and its use for target cell restricted T cell activation | |
| JP2021534220A5 (https=) | ||
| TW201843180A (zh) | 具有肌營養不良蛋白聚糖和層黏連結蛋白－２特異性的多特異性結合分子 | |
| KR102884943B1 (ko) | 개선된 항-flt3 항원 결합 단백질 | |
| US12473369B2 (en) | Fusion protein of anti-eta antibody and tgf-beta trap and pharmaceutical composition and application thereof in method of treatment | |
| KR20180132731A (ko) | 재조합 정맥내 면역글로불린(rIVIG) 조성물 및 이의 제조 및 사용 방법 | |
| JP2022530068A5 (https=) | ||
| US20240279324A1 (en) | Multispecific antagonists | |
| CA3111462C (en) | Improved anti-flt3 antigen binding proteins | |
| US20230391880A1 (en) | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof | |
| KR20230123923A (ko) | 항-EphA4 항체 | |
| KR20230118573A (ko) | 액티빈/tgf-베타 및 rankl의 이작용성 길항제 및 이의 용도 |